Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02024087 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA